Skip to main content
Clinical Trials/NCT03788369
NCT03788369
Terminated
N/A

Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization, a Non-randomized, Prospective, Open-label Registry in Real-world Practice

Seung-Jung Park1 site in 1 country6 target enrollmentApril 5, 2019

Overview

Phase
N/A
Intervention
Hybrid Coronary Revascularization
Conditions
Percutaneous Coronary Revascularization
Sponsor
Seung-Jung Park
Enrollment
6
Locations
1
Primary Endpoint
a composite event of death, myocardial infarction, TVR(Target Vessel Revascularization), or stroke.
Status
Terminated
Last Updated
17 days ago

Overview

Brief Summary

This study evaluated the effectiveness and safety of Hybrid Coronary Revascularization in real-world practice.

Registry
clinicaltrials.gov
Start Date
April 5, 2019
End Date
April 13, 2026
Last Updated
17 days ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Seung-Jung Park
Responsible Party
Sponsor Investigator
Principal Investigator

Seung-Jung Park

Professor, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Asan Medical Center

Eligibility Criteria

Inclusion Criteria

  • Age 20 and more
  • Hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery)
  • Written consent

Exclusion Criteria

  • Previous CABG(coronary artery bypass graft)
  • Life expectancy ≤1 year

Arms & Interventions

Multivessel coronary artery disease

must include left anterior descending artery

Intervention: Hybrid Coronary Revascularization

Outcomes

Primary Outcomes

a composite event of death, myocardial infarction, TVR(Target Vessel Revascularization), or stroke.

Time Frame: 5 years

Patients who have experienced any one of the following events are considered to have experienced the composite outcome: death, myocardial infarction, TVR(Target Vessel Revascularization), or stroke.

Secondary Outcomes

  • Stent thrombosis(5 years)
  • Procedural success(5 days)
  • a composite event of cardiac death or myocardial infarction(5 years)
  • TVR(Target Vessel Revascularization)(5 years)
  • TLR(Target Lesion Revascularization)(5 years)
  • All death(5 years)
  • Cardiac death(5 years)
  • Myocardial infarction(5 years)
  • a composite event of all death or myocardial infarction(5 years)
  • Cerebrovascular event(5 years)

Study Sites (1)

Loading locations...

Similar Trials